Brought to you by 
G1 enters lung cancer trial collaboration with AstraZeneca
14 May 2021
Executive Summary
G1 Therapeutics Inc. will study its investigational CDK inhibitor G1T38 in combination with AstraZeneca PLC’s EGFR inhibitor Tagrisso (osimertinib) under a recently signed clinical trial collaboration.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Trial Collaborations
- R&D (No Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
G1 enters lung cancer trial collaboration with AstraZeneca
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice